264 related articles for article (PubMed ID: 20480263)
1. Anti-hypertensive drugs and left ventricular hypertrophy: a clinical update.
Milan A; Caserta MA; Avenatti E; Abram S; Veglio F
Intern Emerg Med; 2010 Dec; 5(6):469-79. PubMed ID: 20480263
[TBL] [Abstract][Full Text] [Related]
2. The importance of left ventricular hypertrophy in human hypertension.
Kahan T
J Hypertens Suppl; 1998 Sep; 16(7):S23-9. PubMed ID: 9855028
[TBL] [Abstract][Full Text] [Related]
3. The influence of antihypertensive drug treatment on the prevention and regression of left ventricular hypertrophy.
van Zwieten PA
Cardiovasc Res; 2000 Jan; 45(1):82-91. PubMed ID: 10728317
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
Palmieri V; Devereux RB
Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
[TBL] [Abstract][Full Text] [Related]
5. Left ventricular hypertrophy and clinical outcomes in hypertensive patients.
Ruilope LM; Schmieder RE
Am J Hypertens; 2008 May; 21(5):500-8. PubMed ID: 18437140
[TBL] [Abstract][Full Text] [Related]
6. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease.
Gradman AH; Alfayoumi F
Prog Cardiovasc Dis; 2006; 48(5):326-41. PubMed ID: 16627048
[TBL] [Abstract][Full Text] [Related]
7. Cardiac arrhythmias and left ventricular hypertrophy in systemic hypertension and their influences on prognosis.
Bayés-Genís A; Guindo J; Viñolas X; Tomás L; Elosua R; Duran I; Bayés de Luna A
Am J Cardiol; 1995 Nov; 76(13):54D-59D. PubMed ID: 7495219
[TBL] [Abstract][Full Text] [Related]
8. Left ventricular hypertrophy: how to influence an important risk factor in hypertension.
Agabiti-Rosei E; Muiesan ML
J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098
[TBL] [Abstract][Full Text] [Related]
9. Treatment of left ventricular hypertrophy in hypertensive patients.
Tamargo J; Delpón E; Valenzuela C
Eur Heart J; 1993 Nov; 14 Suppl J():102-6. PubMed ID: 8281952
[TBL] [Abstract][Full Text] [Related]
10. Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review.
Dahlöf B
J Hum Hypertens; 1995 Nov; 9 Suppl 5():S37-44. PubMed ID: 8583480
[TBL] [Abstract][Full Text] [Related]
11. Aortic remodelling following the treatment and regression of hypertensive left ventricular hypertrophy: a cardiovascular magnetic resonance study.
Ripley DP; Negrou K; Oliver JJ; Worthy G; Struthers AD; Plein S; Greenwood JP
Clin Exp Hypertens; 2015; 37(4):308-16. PubMed ID: 25271354
[TBL] [Abstract][Full Text] [Related]
12. Regression of electrocardiographic left ventricular hypertrophy or strain is associated with lower incidence of cardiovascular morbidity and mortality in hypertensive patients independent of blood pressure reduction - A LIFE review.
Bang CN; Devereux RB; Okin PM
J Electrocardiol; 2014; 47(5):630-5. PubMed ID: 25052475
[TBL] [Abstract][Full Text] [Related]
13. Management of hypertension in patients with left ventricular hypertrophy.
Cuspidi C; Sala C; Zanchetti A
Curr Hypertens Rep; 2007 Dec; 9(6):498-505. PubMed ID: 18367014
[TBL] [Abstract][Full Text] [Related]
14. [Impact of arterial hypertension on the heart].
Herpin D
Rev Prat; 1999 Mar; 49(5):491-4. PubMed ID: 10358398
[TBL] [Abstract][Full Text] [Related]
15. A Discrepancy: Calcium Channel Blockers Are Effective for the Treatment of Hypertensive Left Ventricular Hypertrophy but Not as Effective for Prevention of Heart Failure.
Koracevic G; Perisic Z; Stanojkovic M; Stojanovic M; Zdravkovic M; Tomasevic M; Djordjevic D; Mladenovic K; Koracevic M; Trkulja J
Med Princ Pract; 2022; 31(5):454-462. PubMed ID: 36044874
[TBL] [Abstract][Full Text] [Related]
16. [Regression of left ventricular hypertrophy in hypertensive patients].
Bosa Ojeda F; García González M; Domínguez Rodríguez A; Barragán Acea A; Miralles Ibarra JM; Lacalzada Almeida J; de Armas Trujillo D
Rev Esp Cardiol; 1997; 50 Suppl 4():74-6. PubMed ID: 9411592
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the cardiac effects of antihypertensive agents.
Agabiti-Rosei E
J Cardiovasc Pharmacol; 1994; 23 Suppl 5():S42-8. PubMed ID: 7609505
[TBL] [Abstract][Full Text] [Related]
18. [Left ventricular hypertrophy and cardiovascular risk in hypertension].
Amabile G
Ann Cardiol Angeiol (Paris); 1998 Feb; 47(2):86-90. PubMed ID: 9772934
[TBL] [Abstract][Full Text] [Related]
19. Hypertensive left ventricular hypertrophy: pathophysiology, assessment and treatment.
Otterstad JE; Smiseth O; Kjeldsen SE
Blood Press; 1996 Jan; 5(1):5-15. PubMed ID: 8777473
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of subclinical target organ damage for risk assessment and treatment in the hypertensive patients: left ventricular hypertrophy.
Agabiti-Rosei E; Muiesan ML; Salvetti M
J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S104-8. PubMed ID: 16565230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
